Integrated analysis of multiple transcriptomic data identifies ST8SIA6‑AS1 and LINC01093 as potential biomarkers in HBV‑associated liver cancer
- Jianhua Xue
- Hui Zhao
- Yifei Fu
- Xu Liu
- Xiangxiang Wu
Affiliations: Department of Infectious Diseases, Hospital for Infectious Diseases of Pudong District, Shanghai 201318, P.R. China, Department of Traditional Chinese Medicine, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, P.R. China
- Published online on: March 24, 2023 https://doi.org/10.3892/ol.2023.13771
Copyright: © Xue
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
The mechanisms of long‑non‑coding RNAs (lncRNAs) in hepatitis B virus (HBV) infection‑associated liver cancer remain largely unclear. Therefore, the aim of the present study was to investigate the regulatory mechanisms of lncRNAs in this disease. HBV‑liver cancer related transcriptome expression profile data (GSE121248 and GSE55092) from the Gene Expression Omnibus database and survival prognosis information from The Cancer Genome Atlas (TCGA) database were obtained for analysis. The limma package was used to identify the overlapped differentially expressed RNAs (DERs), including DElncRNAs and DEmRNAs, in the GSE121248 and GSE55092 datasets. The screened optimized lncRNA signatures were used to develop a nomogram model based on the GSE121248 dataset, which was validated using the GSE55092 and TCGA datasets. A competitive endogenous RNA (ceRNA) network was constructed based on the screened prognosis‑associated lncRNA signatures from TCGA dataset. In addition, the levels of specific lncRNAs were evaluated in HBV‑infected human liver cancer tissues and cells, and Cell Counting Kit‑8, ELISA and Transwell assays were performed to evaluate the effects of the lncRNAs in HBV‑expressing liver cancer cells. A total of 535 overlapped DERs, including 30 DElncRNAs and 505 DEmRNAs, were identified in the GSE121248 and GSE55092 datasets. An optimized DElncRNA signature comprising 10 lncRNAs was used to establish a nomogram. ST8SIA6‑AS1 and LINC01093 were identified as lncRNAs associated with HBV‑liver cancer prognosis in TCGA dataset, and were applied to construct a ceRNA network. Reverse transcription‑quantitative PCR analysis showed that ST8SIA6‑AS1 was upregulated and LINC01093 was downregulated in HBV‑infected human liver cancer tissues and HBV‑expressing liver cancer cells compared with non‑HBV‑infected controls. ST8SIA6‑AS1 knockdown and LINC01093 overexpression independently reduced the number of copies of HBV DNA, the levels of hepatitis B surface antigen and hepatitis B e antigen, as well as cell proliferation, migration and invasion. In summary, the present study identified ST8SIA6‑AS1 and LINC01093 as two potential biomarkers that may be effective therapeutic targets for HBV‑associated liver cancer.